Key result
Genotype-guided prescribing of clopidogrel after stenting for acute coronary syndrome remains non-routine due to uncertain benefits compared with universal use of newer agents.
Why the study?
Does genotype-guided prescribing of antiplatelet therapy improve outcomes compared to universal use of newer agents in patients with acute coronary syndrome after stenting?
Does genotype-guided prescribing of antiplatelet therapy improve outcomes compared to universal use of newer agents in patients with acute coronary syndrome after stenting?
Answers are grounded in this paper and cite their sources.
This editorial discusses the delayed routine adoption of CYP2C19 genotype-guided antiplatelet therapy in patients with acute coronary syndrome.
More than 3 million people annually in the United States receive prescriptions for the antiplatelet drug clopidogrel after stenting for acute coronary syndrome.1 Although genetic variants that are present in a minority of patients of European ancestry and that predict variable clopidogrel response were identified more than a decade ago, genotype-guided prescribing is not routine, in part owing to uncertain benefits of this approach as compared with universal use of newer agents. In this issue of the Journal, Claassens et al.2 report the results of the CYP2C19 Genotype-Guided Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction Patients — Patient Outcome after . . .
No takes yet. Share an insight, caveat, or question.
Dan M. Roden (2019) conducted an editorial in Acute coronary syndrome. Genotype-guided prescribing of clopidogrel vs. Universal use of newer agents was evaluated. Genotype-guided prescribing of clopidogrel after stenting for acute coronary syndrome remains non-routine due to uncertain benefits compared with universal use of newer agents.
Synapse has enriched 10 related papers. Consider them for comparative context: